Stoke Therapeutics (STOK)CHIEF MEDICAL OFFICER sold ~$27K

~$27K

Approx. value · 1,051 sh @ $26.16

19K

Holds after · shares reported

Traded

Oct 1, 2026

Filed

Oct 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 3, 2026Company filing · Form 8-K · ResultsReported its results
2. Sep 22, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 22, 2026, Edward M. Kaye, M.D. notified the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (the “Company”) of his intent to resign as a Class III director of the Board, and as a member of the Research and Development Committee of the Board, effective September 23, 2026.”
3. Oct 1, 2026 · this disclosureInsiderOfficer sold ~$27K of STOK shares in the open market

What came next

1. Oct 2, 2026InsiderOfficer sold ~$17K of STOK shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Stoke Therapeutics

For Stoke Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its STOK page.

Other recent filings by Barry Ticho, CHIEF MEDICAL OFFICER

• SEC Form 4 at Stoke Therapeutics (STOK)Sep 3, 2025
• SEC Form 4 at Stoke Therapeutics (STOK)Aug 20, 2025
• SEC Form 4 at Stoke Therapeutics (STOK)Aug 5, 2025
• SEC Form 4 at Stoke Therapeutics (STOK)Jul 2, 2025
• SEC Form 4 at Stoke Therapeutics (STOK)Jun 5, 2025

The full history of Barry Ticho, CHIEF MEDICAL OFFICER is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Stoke Therapeutics

• SEC Form 144Oct 2, 2026
• SEC Form 4Oct 2, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRMay 14, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRFeb 17, 2026

Everything OQRO holds on this company is on its STOK page.